FDA Approves Gemtuzumab Ozogamicin for CD33+ Pediatric AML

The US Food and Drug Administration has extended the indication of gemtuzumab ozogamicin (Mylotarg) for newly-diagnosed CD33-positive acute myeloid leukemia to include pediatric patients 1 month and older.

Read the full article here

Related Articles